Published in Stem Cell Res Ther on October 10, 2016
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Brain tumour stem cells. Nat Rev Cancer (2006) 5.84
Why are MSCs therapeutic? New data: new insight. J Pathol (2009) 5.25
The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42
Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol (2010) 4.03
Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal (2011) 3.31
Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant (1995) 2.35
The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer (2009) 1.98
Cancer stem cells in glioblastoma. Genes Dev (2015) 1.91
Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res (2008) 1.88
Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther (2005) 1.85
MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget (2013) 1.64
Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci (2013) 1.64
Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol (2000) 1.61
Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol (2010) 1.60
Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opin Biol Ther (2008) 1.59
A critical challenge: dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction. Int J Cardiol (2013) 1.58
Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury. J Neuroinflammation (2013) 1.53
Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol (2006) 1.44
NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT. Cancer (1965) 1.43
Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells (2009) 1.40
Newcastle disease virus selectively kills human tumor cells. J Surg Res (1992) 1.40
Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol (2006) 1.37
Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J (2012) 1.35
Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells. Cancer Res (2005) 1.33
Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. Stem Cells (2010) 1.29
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol (2012) 1.28
Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res (2014) 1.23
Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget (2013) 1.22
Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J Natl Cancer Inst (1988) 1.20
Oncolytic viruses for induction of anti-tumor immunity. Curr Pharm Biotechnol (2012) 1.18
Oncolytic viral therapy of malignant glioma. Neurotherapeutics (2009) 1.12
Cord blood stem cells revert glioma stem cell EMT by down regulating transcriptional activation of Sox2 and Twist1. Oncotarget (2011) 1.09
TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J Immunol (2003) 1.08
The TRAIL to targeted therapy of breast cancer. Adv Cancer Res (2009) 1.08
Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. J Virol (2010) 1.07
Roles of tyrosine phosphorylation and cleavage of protein kinase Cdelta in its protective effect against tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis. J Biol Chem (2005) 1.07
Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathol (2009) 1.06
Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev (2010) 1.06
Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol Ther (2010) 1.05
Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation. Stem Cells Dev (2013) 1.04
Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol (2012) 1.03
Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther (2010) 1.02
Isolation and characterisation of mesenchymal stem cells derived from human placenta tissue. World J Stem Cells (2012) 1.02
Targeting TRAIL in the treatment of cancer: new developments. Expert Opin Ther Targets (2015) 1.02
Malignant gliomas. Curr Treat Options Oncol (2000) 1.00
Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother (1994) 0.99
Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther (2009) 0.97
Progress in stem cell therapy for major human neurological disorders. Stem Cell Rev (2013) 0.97
Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario. Int J Cancer (2013) 0.96
Viruses in the treatment of cancer. Lancet (1970) 0.95
Live viruses in cancer treatment. Oncology (Williston Park) (2002) 0.95
The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders. Clin Neurol Neurosurg (2008) 0.95
Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions. Cell Signal (2011) 0.93
Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Cancer Biol Ther (2014) 0.92
Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res (1999) 0.91
Viruses in the treatment of cancer. Lancet (1971) 0.90
TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo. Neuro Oncol (2012) 0.88
TRAIL, a mighty apoptosis inducer. Mol Cells (2003) 0.88
A comparison of human cord blood- and embryonic stem cell-derived endothelial progenitor cells in the treatment of chronic wounds. Biomaterials (2012) 0.85
Migration of mesenchymal stem cells towards glioblastoma cells depends on hepatocyte-growth factor and is enhanced by aminolaevulinic acid-mediated photodynamic treatment. Biochem Biophys Res Commun (2013) 0.83
Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy. J Virol (2013) 0.81
Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy. Immunol Lett (2014) 0.81
Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus. Curr Opin Virol (2015) 0.80
ISG12a mediates cell response to Newcastle disease viral infection. Virology (2014) 0.79
Umbilical cord-derived mesenchymal stem cell therapy for neurological disorders via inhibition of mitogen-activated protein kinase pathway-mediated apoptosis. Mol Med Rep (2014) 0.77
RTVP-1 promotes mesenchymal transformation of glioma via a STAT-3/IL-6-dependent positive feedback loop. Oncotarget (2015) 0.77
Sensitivity of Human Malignant Melanoma Cell Lines to Newcastle Disease Virus. Anticancer Res (2015) 0.76